

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Viginia 22313-1450 www.uspto.gov

ATTORNEY DOCKET NO. CONFIRMATION NO. APPLICATION NO. FILING DATE. FIRST NAMED INVENTOR UCSD1530-2 8484 William Fenical 10/600,854 06/20/2003 EXAMINER 12/30/2004 GRAY CARY WARE & FREIDENRICH LLP POWERS, FIONA 4365 EXECUTIVE DRIVE PAPER NUMBER ART UNIT **SUITE 1100** SAN DIEGO, CA 92121-2133 1626

DATE MAILED: 12/30/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

| | Application No. | Applicant(s) |
|---|---|------------------------------|
| Office Action Summary | 10/600,854 | FENICAL ET AL. |
| | Examiner | Art Unit |
| | Fiona T. Powers | 1626 |
| The MAILING DATE of this communication ap | li di | correspondence address |
| Period for Reply | | |
| A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). | | |
| Status | | |
| 1) Responsive to communication(s) filed on <u>06 December 2004</u> . | | |
| 2a) ☐ This action is FINAL . 2b) ☑ Th | is action is non-final. | , |
| 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is | | |
| closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213. | | |
| Disposition of Claims | | |
| 4) Claim(s) 2-6,8,9,11,15-21 and 23 to 29 is/are pending in the application. | | |
| 4a) Of the above claim(s) 15-21 and 27 to 29 is/are withdrawn from consideration. | | |
| 5) Claim(s) is/are allowed. | | |
| 6)⊠ Claim(s) <u>2-6, 8 and 23 to 26</u> is/are rejected. | | |
| 7)⊠ Claim(s) <u>9 and 11</u> is/are objected to. | | |
| 8) Claim(s) are subject to restriction and/or election requirement. | | |
| Application Papers | | |
| 9) The specification is objected to by the Examiner. | | |
| 10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner. | | |
| Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). | | |
| Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). | | |
| 11)☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152. | | |
| Priority under 35 U.S.C. § 119 | | |
| 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). | | |
| a) ☐ All b) ☐ Some * c) ☐ None of: 1. ☐ Certified copies of the priority documents have been received. | | |
| 2. Certified copies of the priority documents have been received in Application No | | |
| 3. Copies of the certified copies of the priority documents have been received in this National Stage | | |
| application from the International Bureau (PCT Rule 17.2(a)). | | |
| * See the attached detailed Office action for a list of the certified copies not received. | | |
| | | |
| · · · · · · · · · · · · · · · · · · · | * | : |
| Attachment(s) | | |
| 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) | 4) Interview Summar Paper No(s)/Mail D | |
| 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/0 | 08) 5) Notice of Informal | Patent Application (PTO-152) |
| Paper No(s)/Mail Date <u>11/15/04</u> . 6) Other: | | |

Application/Control Number: 10/600,854
Art Unit: 1626

Receipt is acknowledged of the preliminary amendment filed May 3, 2004 and the information disclosure statement filed November 15, 2004, which have been entered in the file.

Applicant's election of Group I, claims 2 to 6, 8, 9, 11 and 23 to 26 in the reply filed on December 6, 2004 is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.03(a)).

Claims 15 to 21 and 27 to 29 stand withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on December 6, 2004.

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 23 and 2 and 4 to 6 are rejected under 35
U.S.C. 112, second paragraph, as being indefinite for failing to
particularly point out and distinctly claim the subject matter
which applicant regards as the invention.

Application/Control Number: 10/600,854

Art Unit: 1626

Variables R_1 , R_2 and R_3 are monovalent radicals but are defined as sulfonyl which is a divalent radical. It is not clear what else is bonded to the sulfonyl radical.

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.

Claims 2 to 6, 23 and 24 are rejected under 35 U.S.C. 102(a) as being anticipated by Fenical et al. (WO 02/47610), cited.

The reference discloses the claimed compound of the formula I wherein E_1 , E_3 and E_4 are O, E_2 is NH, R_1 is chloroethyl, R_2 is methyl, R_3 is hydroxy and x is 0. Note Figure 1.

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Art Unit: 1626

Claims 8, 25 and 26 are rejected under 35 U.S.C. 103(a) as being unpatentable over Fenical et al. (WO 02/47610).

Determination of the scope and content of the prior art (MPEP §2141.01)

The reference discloses the compound of the formula I wherein E_1 , E_3 and E_4 are O, E_2 is NH, R_1 is chloroethyl, R_2 is methyl, R_3 is hydroxy and x is 0 which is the compound of instant claim 24. Note Figure 1. The reference also discloses that the compound (known as salinosporamide A) has pharmaceutical activity as a potent anticancer agent. Note page 9, last paragraph to page 10, first paragraph.

Ascertainment of the difference between the prior art and the claims (MPEP §2141.02)

The difference between the reference and what is claimed is that the reference does not disclose a pharmaceutical composition containing the compound.

Finding of prima facie obviousness---rational and motivation (MPEP §2142-2413)

However, since the compound has pharmaceutical acitivity it would have been obvious to one of ordinary skill in the art to prepare a pharmaceutical composition containing the compound.

One of ordinary skill in the art would have been motivated to make the claimed composition with the expectation that pharmaceutical compositions with anticancer activity would be obtained.

Application/Control Number: 10/600,854

Art Unit: 1626

Claims 9 and 11 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

The references made of record and not relied upon show the state of the art.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Fiona T. Powers whose telephone number is (571)272-0702. The examiner can normally be reached on Monday - Friday 8:00 AM to 4:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Joseph K. McKane can be reached on (571)272-0699. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Art Unit: 1626

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Fiona T. Powers
Primary Examiner
Art Unit 1626

ftp December 23, 2004